Camurus at a glance
Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic diseases.
New medicinal products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of opioid dependence and pain, endocrine diseases and cancer and supportive care, which are developed in-house and in collaboration with international pharmaceutical companies. Camurus has over 170 employees with headquarters in Lund (Sweden), and larger regional offices in Cambridge (UK), Mannheim (Germany) and Sydney (Australia). The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”.
Making a difference
Camurus is committed to lead the development of advanced drug delivery systems and innovative medical products to improve quality of life for patients with severe and chronic diseases.
Combining R&D expertise and world-leading technology
Streamlining development of innovative, long-acting medicines – for the benefit of patients, the healthcare system and shareholders.